Immunotherapy for brain tumors: quo vadis?

References

• Parney IF, Farr-Jones MA, Kane K et al. Human autologous in vitro models of glioma immunogene therapy using B7-2, GM-CSF, and IL-12. Can. J. Neurol. Sci.29(3), 267–275 (2002).
   PubMed Web of Science ®Google Scholar
• Parney IF, Petruk KC, Zhang C et al. Granulocyte-macrophage colony-stimulating factor and B7-2 combination immunogene therapy in an allogeneic Hu-PBL-SCID/beige mouse-human glioblastoma multiforme model. Hum. Gene Ther.8(9), 1073–1085 (1997).
   PubMed Web of Science ®Google Scholar
• Jean WC, Spellman SR, Wallenfriedman MA et al. Effects of combined granulocyte–macrophage colony-stimulating factor (GM-CSF), interleukin-2, and interleukin-12 based immunotherapy against intracranial glioma in the rat. J. Neurooncol.66(1–2), 39–49 (2004).
   PubMed Web of Science ®Google Scholar
• Wallenfriedman MA, Conrad JA, DelaBarre L et al. Effects of continuous localized infusion of granulocyte–macrophage colony-stimulating factor and inoculations of irradiated glioma cells on tumor regression. J. Neurosurg.90(6), 1064–1071 (1999).
   PubMed Web of Science ®Google Scholar
• Herrlinger U, Kramm CM, Johnston KM et al. Vaccination for experimental gliomas using GM-CSF-transduced glioma cells.Cancer Gene Ther.4(6), 345–352 (1997).
   PubMed Web of Science ®Google Scholar
• Lefranc F, Cool V, Velu T et al. Granulocyte macrophage-colony stimulating factor gene transfer to induce a protective anti-tumoral immune response against the 9L rat gliosarcoma model.Int. J. Oncol.20(5), 1077–1085 (2002).
   PubMed Web of Science ®Google Scholar
• Sampson JH, Archer GE, Ashley DM et al. Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the ‘immunologically privileged’ central nervous system.Proc. Natl Acad. Sci. USA93(19), 10399–10404 (1996).
   PubMed Web of Science ®Google Scholar
• Wakimoto H, Abe J, Tsunoda R et al. Intensified antitumor immunity by a cancer vaccine that produces granulocyte–macrophage colony-stimulating factor plus interleukin 4.Cancer Res.56(8), 1828–1833 (1996).
   PubMed Web of Science ®Google Scholar
• Yu JS, Burwick JA, Dranoff G et al. Gene therapy for metastatic brain tumors by vaccination with granulocyte–macrophage colony-stimulating factor-transduced tumor cells.Hum. Gene Ther.8(9), 1065–1072 (1997).
   PubMed Web of Science ®Google Scholar
• Sobol RE, Fakhrai H, Shawler D et al. Interleukin-2 gene therapy in a patient with glioblastoma.Gene Ther.2(2), 164–167 (1995).
   PubMed Web of Science ®Google Scholar
• Lichtor T, Glick RP. Cytokine immuno-gene therapy for treatment of brain tumors.J. Neurooncol.65(3), 247–259 (2003).
   PubMed Web of Science ®Google Scholar
• Lichtor T, Glick RP, Tarlock K et al. Application of interleukin-2-secreting syngeneic/allogeneic fibroblasts in the treatment of primary and metastatic brain tumors.Cancer Gene Ther.9(5), 464–469 (2002).
   PubMed Web of Science ®Google Scholar
• Glick RP, Lichtor T, Panchal R, Mahendra A, Cohen EP. Treatment with allogeneic interleukin-2 secreting fibroblasts protects against the development of malignant brain tumors. J. Neurooncol.64(1–2), 139–146 (2003).
   PubMed Web of Science ®Google Scholar
• Ishikawa E, Tsuboi K, Takano S et al. Intratumoral injection of IL-2-activated NK cells enhances the antitumor effect of intradermally injected paraformaldehyde-fixed tumor vaccine in a rat intracranial brain tumor model. Cancer Sci.95(1), 98–103 (2004).
   PubMed Web of Science ®Google Scholar
• Iwadate Y, Yamaura A, Sato Y et al. Induction of immunity in peripheral tissues combined with intracerebral transplantation of interleukin-2-producing cells eliminates established brain tumors.Cancer Res.61(24), 8769–8774 (2001).
   PubMed Web of Science ®Google Scholar
• Dillman RO, Duma CM, Schiltz PM et al. Intracavitary placement of autologous lymphokine-activated killer (LAK) cells after resection of recurrent glioblastoma.J. Immunother.27(5), 398–404 (2004).
   PubMed Web of Science ®Google Scholar
• Rhines LD, Sampath P, DiMeco F et al. Local immunotherapy with interleukin-2 delivered from biodegradable polymer microspheres combined with interstitial chemotherapy: a novel treatment for experimental malignant glioma. Neurosurgery52(4), 872–879; (2003).
   PubMed Web of Science ®Google Scholar
• Okada H, Villa L, Attanucci J et al. Cytokine gene therapy of gliomas: effective induction of therapeutic immunity to intracranial tumors by peripheral immunization with interleukin-4 transduced glioma cells.Gene Ther.8(15), 1157–1166 (2001).
   PubMed Web of Science ®Google Scholar
• Okada H, Giezeman-Smits KM, Tahara H et al. Effective cytokine gene therapy against an intracranial glioma using a retrovirally transduced IL-4 plus HSVtk tumor vaccine.Gene Ther.6(2), 219–226 (1999).
   PubMed Web of Science ®Google Scholar
• Okada H, Lieberman FS, Edington HD et al. Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of recurrent glioblastoma: preliminary observations in a patient with a favorable response to therapy.J. Neurooncol.64(1–2), 13–20 (2003).
   PubMed Web of Science ®Google Scholar
• Iwadate Y, Namba H, Sakiyama S et al. Interleukin-12-mediated induction of systemic immunity in the periphery and recruitment of activated T cells into the brain produce limited antitumor effects compared with interleukin-2. Int. J. Mol. Med.10(6), 741–747 (2002).
   PubMed Web of Science ®Google Scholar
• DiMeco F, Rhines LD, Hanes J et al. Paracrine delivery of IL-12 against intracranial 9L gliosarcoma in rats. J. Neurosurg.92(3), 419–427 (2000).
   PubMed Web of Science ®Google Scholar
• Ehtesham M, Kabos P, Kabosova A et al. The use of interleukin 12-secreting neural stem cells for the treatment of intracranial glioma.Cancer Res.62(20), 5657–5663 (2002).
   PubMed Web of Science ®Google Scholar
• Yang SY, Liu H, Zhang JN. Gene therapy of rat malignant gliomas using neural stem cells expressing IL-12. DNA Cell Biol.23(6), 381–389 (2004).
   PubMed Web of Science ®Google Scholar
• Kishima H, Shimizu K, Miyao Y et al. Systemic interleukin 12 displays anti-tumour activity in the mouse central nervous system.Br. J. Cancer78(4), 446–453 (1998).
   PubMed Web of Science ®Google Scholar
• Roy EJ, Gawlick U, Orr BA et al. IL-12 treatment of endogenously arising murine brain tumors.J. Immunol.165(12), 7293–7299 (2000).
   PubMed Web of Science ®Google Scholar
• Insug O, Ku G, Ertl HC et al. A dendritic cell vaccine induces protective immunity to intracranial growth of glioma.Anticancer Res.22(2A), 613–621 (2002).
   PubMed Web of Science ®Google Scholar
• Kikuchi T, Akasaki Y, Abe T et al. Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12. J. Immunother.27(6), 452–459 (2004).
   PubMed Web of Science ®Google Scholar
• Ni HT, Spellman SR, Jean WC et al. Immunization with dendritic cells pulsed with tumor extract increases survival of mice bearing intracranial gliomas.J. Neurooncol.51(1), 1–9 (2001).
   PubMed Web of Science ®Google Scholar
• Saito R, Mizuno M, Nakahara N et al. Vaccination with tumor cell lysate-pulsed dendritic cells augments the effect of IFN-β gene therapy for malignant glioma in an experimental mouse intracranial glioma. Int. J. Cancer111(5), 777–782 (2004).
   PubMed Web of Science ®Google Scholar
• Caruso DA, Orme LM, Neale AM et al. Results of a Phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer.Neurooncology6(3), 236–246 (2004).
   PubMed Web of Science ®Google Scholar
• De Vleeschouwer S, Van Calenbergh F, Demaerel P et al. Transient local response and persistent tumor control in a child with recurrent malignant glioma: treatment with combination therapy including dendritic cell therapy. Case report.J. Neurosurg. Spine100(5), 492–497 (2004).
   PubMed Web of Science ®Google Scholar
• Rutkowski S, De Vleeschouwer S, Kaempgen E et al. Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study.Br. J. Cancer91(9), 1656–1662 (2004).
   PubMed Web of Science ®Google Scholar
• Yamanaka R, Abe T, Yajima N et al. Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical Phase I/II trial.Br. J. Cancer89(7), 1172–1179 (2003).
   PubMed Web of Science ®Google Scholar
• Yu JS, Liu G, Ying H et al. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma.Cancer Res.64(14), 4973–4979 (2004).
   PubMed Web of Science ®Google Scholar
• Yu JS, Wheeler CJ, Zeltzer PM et al. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration.Cancer Res.61(3), 842–847 (2001).
   PubMed Web of Science ®Google Scholar
• Ehtesham M, Kabos P, Gutierrez MA et al. Intratumoral dendritic cell vaccination elicits potent tumoricidal immunity against malignant glioma in rats.J. Immunother.26(2), 107–116 (2003).
   PubMed Web of Science ®Google Scholar
• Kikuchi T, Akasaki Y, Abe T et al. Intratumoral injection of dendritic and irradiated glioma cells induces anti-tumor effects in a mouse brain tumor model.Cancer Immunol. Immunother.51(8), 424–430 (2002).
   PubMed Web of Science ®Google Scholar
• Yamanaka R, Tsuchiya N, Yajima N et al. Induction of an antitumor immunological response by an intratumoral injection of dendritic cells pulsed with genetically engineered Semliki Forest virus to produce interleukin-18 combined with the systemic administration of interleukin-12.J. Neurosurg.99(4), 746–753 (2003).
   PubMed Web of Science ®Google Scholar
• Andreansky S, He B, van Cott J et al. Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins.Gene Ther.5(1), 121–130 (1998).
   PubMed Web of Science ®Google Scholar
• Miyatake S, Martuza RL, Rabkin SD. Defective herpes simplex virus vectors expressing thymidine kinase for the treatment of malignant glioma.Cancer Gene Ther.4(4), 222–228 (1997).
   PubMed Web of Science ®Google Scholar
• Parker JN, Gillespie GY, Love CE et al. Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors.Proc. Natl Acad. Sci. USA97(5), 2208–2213 (2000).
   PubMed Web of Science ®Google Scholar
• Hellums EK, Markert JM, Parker JN et al. Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma model. Neurooncology7(3), 213–224 (2005).
   PubMed Web of Science ®Google Scholar